Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate

Jeffrey T. Jensen, Susanne Parke, Uwe Mellinger, Marco Serrani, R. Garn Mabey
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2013 · vol. 18(4) , pp. 274–283 · doi:10.3109/13625187.2013.785516 · PMID:23638631 · W2122822080
RCT OA: closed CC0 ⤵ 13 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Oestradiol valerate/dienogest significantly reduced headache and pelvic pain during hormone withdrawal more than ethinylestradiol/norgestimate in women experiencing these symptoms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To determine the effect of oestradiol valerate/dienogest (E2V/DNG) versus ethinylestradiol/norgestimate (EE/NGM) on hormone-withdrawal associated symptoms (HWAS) in otherwise healthy women who had experienced at least one of these symptoms when using 21/7-day combined oral contraceptives (COCs). METHODS: This phase III, parallel-group study randomised 409 women aged 18 to 50 years to E2V/DNG or EE/NGM. The primary efficacy variable was the change from baseline to cycle 6 in the average of the three highest visual analogue scale values for headache and/or pelvic pain during cycle days 22 to 28. RESULTS: In total, 395 were included in the full analysis set (E2V/DNG, n = 191; EE/NGM, n = 204). E2V/DNG reduced the symptoms of headache or pelvic pain during cycle days 22 to 28 from baseline to cycle 6 to a significantly greater extent than EE/NGM (mean decrease 43.6 vs. 35.5 mm; p = 0.0024). Both treatments were well tolerated with a similar proportion of women experiencing adverse events that were considered at least possibly related to treatment (35% E2V/DNG vs. 34% EE/NGM). CONCLUSIONS: E2V/DNG reduces the frequency and intensity of headache and pelvic pain to a greater extent than EE/NGM, and may be a good option for women susceptible to HWAS with conventional 21/7-day COCs.

My notes (saved in your browser only)

MeSH descriptors

Contraceptives, Oral Estradiol Ethinyl Estradiol Headache Nandrolone Norgestrel Pelvic Pain Substance Withdrawal Syndrome Adult Contraceptives, Oral Contraceptives, Oral Double-Blind Method Drug Combinations Estradiol Estradiol Estradiol Ethinyl Estradiol Ethinyl Estradiol Female Headache

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (28)

Cited by (8)

Source provenance

openalex
last seen: 2026-05-11T04:57:49.206141+00:00
pubmed
last seen: 2026-10-08T21:11:51.557491+00:00
unpaywall
last seen: 2026-10-21T06:41:41.500114+00:00
License: CC0 · commercial use OK